Kossoy George, Ben-Hur Herzl, Elhayany Asher, Schneider David F, Zusman Itshak
Laboratory of Experimental Oncology, The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel.
Oncol Rep. 2005 Apr;13(4):585-8.
This study examined whether soluble 66 and 51 kDa tumor-associated antigens (sTAA), isolated from the serum of rats with mammary cancer, possess specific suppressive effects on chemically-induced mammary tumorigenesis in syngeneic counterparts. Dimethylbenzanthracene (DMBA, 10 mg/rat, two administrations) was used to induce mammary tumors in 8-week-old Sprague Dawley rats. After the appearance of numerous tumors, preparations of sTAA (50 to 60 microg/rat in 0.5 ml sterile PBS) obtained from breast cancer patients (heterologous sTAA) or from syngeneic mammary tumor-bearing rats (syngeneic sTAA) were administered weekly for 12 weeks. The following groups of mammary tumor-bearing rats were studied: groups 1 and 3, control rats treated with saline; group 2, rats treated with heterologous sTAA; and group 4, rats treated with syngeneic sTAA. The experiment was terminated when tumors in 50% of the rats became ulcerous. The treatment with both types of sTAA significantly decreased, compared to controls and initial values, the yield and total area of the tumors. We conclude that syngeneic sTAA have tumor-suppressive properties, which are very similar to those in heterologous sTAA.
本研究检测了从乳腺癌大鼠血清中分离出的可溶性66 kDa和51 kDa肿瘤相关抗原(sTAA),对同基因对照大鼠化学诱导的乳腺肿瘤发生是否具有特异性抑制作用。用二甲基苯并蒽(DMBA,10 mg/只大鼠,分两次给药)诱导8周龄斯普拉格-道利大鼠发生乳腺肿瘤。在出现大量肿瘤后,每周给荷瘤大鼠注射从乳腺癌患者(异源sTAA)或同基因乳腺荷瘤大鼠(同基因sTAA)获得的sTAA制剂(50至60 μg/只大鼠,溶于0.5 ml无菌PBS中),共注射12周。对以下几组乳腺荷瘤大鼠进行了研究:第1组和第3组,用生理盐水处理的对照大鼠;第2组,用异源sTAA处理的大鼠;第4组,用同基因sTAA处理的大鼠。当50%的大鼠肿瘤出现溃疡时终止实验。与对照组和初始值相比,两种类型的sTAA处理均显著降低了肿瘤的发生率和总面积。我们得出结论,同基因sTAA具有肿瘤抑制特性,这与异源sTAA的特性非常相似。